Compare RANI & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | PRE |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.6M | 131.3M |
| IPO Year | 2021 | N/A |
| Metric | RANI | PRE |
|---|---|---|
| Price | $1.40 | $16.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | $8.67 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.6M | 141.5K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,200,000.00 | ★ $77,079,000.00 |
| Revenue This Year | $414.59 | $219.28 |
| Revenue Next Year | $30.15 | $124.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 201.54 |
| 52 Week Low | $0.39 | $3.10 |
| 52 Week High | $3.87 | $18.48 |
| Indicator | RANI | PRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 57.43 |
| Support Level | $1.40 | $16.17 |
| Resistance Level | $1.53 | $18.48 |
| Average True Range (ATR) | 0.11 | 1.24 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 15.00 | 60.49 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.